91 related articles for article (PubMed ID: 19298850)
1. Immoderate inhibition of estrogen by anastrozole enhances the severity of experimental polyarthritis.
Wang J; Zhang Q; Jin S; Feng M; Kang X; Zhao S; Liu S; Zhao W
Exp Gerontol; 2009; 44(6-7):398-405. PubMed ID: 19298850
[TBL] [Abstract][Full Text] [Related]
2. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
Miller WR; Stuart M; Sahmoud T; Dixon JM
Br J Cancer; 2002 Oct; 87(9):950-5. PubMed ID: 12434282
[TBL] [Abstract][Full Text] [Related]
3. Focus on anastrozole and breast cancer.
Mokbel K
Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
[TBL] [Abstract][Full Text] [Related]
4. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
5. Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer.
Sawada S; Sato K; Kusuhara M; Ayaori M; Yonemura A; Tamaki K; Hiraide H; Mochizuki H; Ohsuzu F
Acta Oncol; 2005; 44(2):134-41. PubMed ID: 15788292
[TBL] [Abstract][Full Text] [Related]
6. Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
Itoh T; Karlsberg K; Kijima I; Yuan YC; Smith D; Ye J; Chen S
Mol Cancer Res; 2005 Apr; 3(4):203-18. PubMed ID: 15831674
[TBL] [Abstract][Full Text] [Related]
7. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
Briot K; Tubiana-Hulin M; Bastit L; Kloos I; Roux C
Breast Cancer Res Treat; 2010 Feb; 120(1):127-34. PubMed ID: 20035381
[TBL] [Abstract][Full Text] [Related]
8. Refining the postmenopausal breast cancer treatment paradigm: the FACE trial.
Monnier A
Expert Rev Anticancer Ther; 2006 Oct; 6(10):1355-9. PubMed ID: 17069521
[TBL] [Abstract][Full Text] [Related]
9. ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer.
Buzdar AU; Jonat W; Howell A; Plourde PV
J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):145-9. PubMed ID: 9365184
[TBL] [Abstract][Full Text] [Related]
10. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
McCaig FM; Renshaw L; Williams L; Young O; Murray J; Macaskill EJ; McHugh M; Hannon R; Dixon JM
Breast Cancer Res Treat; 2010 Feb; 119(3):643-51. PubMed ID: 19941160
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators.
Geisler J
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):245-53. PubMed ID: 14623518
[TBL] [Abstract][Full Text] [Related]
12. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
13. Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?
Lewis S
Am Heart J; 2007 Feb; 153(2):182-8. PubMed ID: 17239675
[TBL] [Abstract][Full Text] [Related]
14. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Belosay A; Brodie AM; Njar VC
Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
[TBL] [Abstract][Full Text] [Related]
15. Anastrozole (Arimidex)--an aromatase inhibitor for the adjuvant setting?
Buzdar AU
Br J Cancer; 2001 Nov; 85 Suppl 2(Suppl 2):6-10. PubMed ID: 11900212
[TBL] [Abstract][Full Text] [Related]
16. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study.
Dixon JM; Renshaw L; Bellamy C; Stuart M; Hoctin-Boes G; Miller WR
Clin Cancer Res; 2000 Jun; 6(6):2229-35. PubMed ID: 10873072
[TBL] [Abstract][Full Text] [Related]
17. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
18. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
[TBL] [Abstract][Full Text] [Related]
19. Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.
Buzdar AU
Expert Rev Anticancer Ther; 2002 Dec; 2(6):623-9. PubMed ID: 12503208
[TBL] [Abstract][Full Text] [Related]
20. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]